Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of subcutaneous ONO-4915 in primary Sjogren's disease
jRCT2011260036Phase 2Not yet recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Oct 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in primary Sjögren's syndrome comparing ONO-4915 with Placebo (2 arms). Primary endpoint: Change from baseline in ESSPRI score at Week 24. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ONO-4915
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on jRCT2011260036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011260036.